<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778985</url>
  </required_header>
  <id_info>
    <org_study_id>STU-042011-101</org_study_id>
    <nct_id>NCT01778985</nct_id>
  </id_info>
  <brief_title>Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor</brief_title>
  <acronym>PET</acronym>
  <official_title>Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Urogynecologic Society Foundation Astellas Research Award</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine how vaginal estrogen cream given for several weeks before pelvic
      reconstructive therapy will effect elastic fiber assembly in the muscularis layer of the
      vaginal wall. Postmenopausal women with at least Stage 2 pelvic organ prolapse will receive
      either estrogen vaginal cream or placebo cream 6-8 weeks prior to reconstructive surgery. At
      time of surgery, full thickness biopsies will be obtained from a standardized location at the
      top of vagina. The investigators will measure the thickness of the vaginal muscularis,
      elastic fiber number and morphology, and analyze if elastic fiber synthesis or degradation is
      affected by estrogen therapy. The results will provide important data to support a larger
      clinical trial to determine if preoperative and maintenance estrogen therapy alter long-term
      success rates of pelvic reconstructive surgery for pelvic organ prolapse.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal Wall Composition: Epithelium (Intention to Treat)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Will assess vaginal wall histology - thicknesses of epithelium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Wall Composition: Epithelium (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Will assess vaginal wall histology - thicknesses of epithelium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Wall Composition: Muscularis (Intention to Treat)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Will assess vaginal wall histology - thicknesses of muscularis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Wall Composition: Muscularis (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Will assess vaginal wall histology - thicknesses of muscularis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hCOL1A1, Per-Protocol</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Collagen Content in Vaginal Muscularis, (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Will assess hydroxy-proline assays as index of amount of collagen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Wall Degradative Activity, Muscularis, MMP-9</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Will assess zymograms for total matrix metalloprotease (MMP) 9 activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Wall Composition: Lamina Propria (Intention to Treat)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Will assess vaginal wall histology - thickness of lamina propria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Wall Composition: Lamina Propria (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. 6-8 weeks of intervention</time_frame>
    <description>Will assess vaginal wall histology - thickness of lamina propria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hCOL3, (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lysyl Oxidase (LOX) (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LOXL1 (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tropoelastin (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TGFB1 (Per-Protocol)</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaginal Wall Degradative Activity, Mucosa, MMP-9</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Will assess zymograms for total matrix metalloprotease (MMP) 9 activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Estrone Levels, Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estrone Levels, Surgery</measure>
    <time_frame>Time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estradiol Levels, Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Estradiol Levels, Surgery</measure>
    <time_frame>Time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Blood Loss</measure>
    <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
    <description>Intraoperative estimated blood loss</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>Premarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Premarin</intervention_name>
    <arm_group_label>Premarin</arm_group_label>
    <other_name>Conjugated equine estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women, still with uterus, planning total hysterectomy as part of surgical repair for
             pelvic organ prolapse

          -  Symptomatic anterior and/or apical vaginal prolapse greater than or equal to Stage 2
             (i.e., bulge extends to at least 1 cm of the hymen or beyond)

          -  Women between 1 and 10 years after menopause. Menopause is defined as one year of
             amenorrhea or surgical ovariectomy.

          -  Age 40-70 years old

          -  No estrogen replacement therapy in the last 1 month

          -  Physically capable of daily application of vaginal cream

        Exclusion Criteria:

          -  BMI &gt;35

          -  Prior surgical repair of prolapse involving the vaginal cuff.

          -  Prior total hysterectomy

          -  Premenopausal or postmenopausal &gt;10 years

          -  Prior steroid hormone replacement therapy of duration &gt;1 month (oral or vaginal
             estrogen, testosterone or corticosteroids)

          -  History of connective tissue disease (Ehlers-Danlos, Marfan, etc)

          -  History of vaginal radiation

          -  Contraindications for estrogen replacement therapy (current, or history of,
             spontaneous deep vein thrombosis, stroke, coronary artery disease, breast or
             endometrial cancer)

          -  Concurrent use of steroid cream for treatment of Lichen sclerosis

          -  Recent history (within last month) of vaginal infection or vaginitis

          -  Current tobacco use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <results_first_submitted>May 20, 2014</results_first_submitted>
  <results_first_submitted_qc>August 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2014</results_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>David Rahn, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Dept. of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>Pelvic organ prolapse</keyword>
  <keyword>Menopause</keyword>
  <keyword>Estrogen</keyword>
  <keyword>Premarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Premarin</title>
          <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Premarin</title>
          <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="5.4"/>
                    <measurement group_id="B2" value="58.9" spread="5.1"/>
                    <measurement group_id="B3" value="57.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Hispanic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>deliveries</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="B2" value="4" lower_limit="3" upper_limit="6"/>
                    <measurement group_id="B3" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="5.4"/>
                    <measurement group_id="B2" value="31.7" spread="4.1"/>
                    <measurement group_id="B3" value="30.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vaginal Wall Composition: Epithelium (Intention to Treat)</title>
        <description>Will assess vaginal wall histology - thicknesses of epithelium</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>Patients completing surgery with biopsy specimens available for analysis (&quot;intention to treat&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vaginal Wall Composition: Epithelium (Intention to Treat)</title>
          <description>Will assess vaginal wall histology - thicknesses of epithelium</description>
          <population>Patients completing surgery with biopsy specimens available for analysis (&quot;intention to treat&quot;)</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.9" spread="63.7"/>
                    <measurement group_id="O2" value="314.1" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaginal Wall Composition: Epithelium (Per-Protocol)</title>
        <description>Will assess vaginal wall histology - thicknesses of epithelium</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>Patients completing surgery with biopsy specimens available for analysis and who were adherent to study medication (&quot;per protocol&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vaginal Wall Composition: Epithelium (Per-Protocol)</title>
          <description>Will assess vaginal wall histology - thicknesses of epithelium</description>
          <population>Patients completing surgery with biopsy specimens available for analysis and who were adherent to study medication (&quot;per protocol&quot;)</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.5" spread="45.1"/>
                    <measurement group_id="O2" value="314.1" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaginal Wall Composition: Muscularis (Intention to Treat)</title>
        <description>Will assess vaginal wall histology - thicknesses of muscularis</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>Patients completing surgery with biopsy specimens available for analysis (&quot;intention to treat&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vaginal Wall Composition: Muscularis (Intention to Treat)</title>
          <description>Will assess vaginal wall histology - thicknesses of muscularis</description>
          <population>Patients completing surgery with biopsy specimens available for analysis (&quot;intention to treat&quot;)</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5670.4" spread="2154.7"/>
                    <measurement group_id="O2" value="2807.1" spread="622.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaginal Wall Composition: Muscularis (Per-Protocol)</title>
        <description>Will assess vaginal wall histology - thicknesses of muscularis</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>Patients completing surgery with biopsy specimens available for analysis and who were adherent to study medication (&quot;per protocol&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vaginal Wall Composition: Muscularis (Per-Protocol)</title>
          <description>Will assess vaginal wall histology - thicknesses of muscularis</description>
          <population>Patients completing surgery with biopsy specimens available for analysis and who were adherent to study medication (&quot;per protocol&quot;)</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7570.7" spread="3193.1"/>
                    <measurement group_id="O2" value="2807.1" spread="622.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>t(18)=1.78, p=0.088</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>hCOL1A1, Per-Protocol</title>
        <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>Patients completing surgery with biopsy specimens available for analysis and who were adherent to study medication (&quot;per protocol&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>hCOL1A1, Per-Protocol</title>
          <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
          <population>Patients completing surgery with biopsy specimens available for analysis and who were adherent to study medication (&quot;per protocol&quot;)</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="1.52" upper_limit="2.91"/>
                    <measurement group_id="O2" value="0.37" lower_limit="0.18" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Estrone Levels, Baseline</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estrone Levels, Baseline</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="2.3"/>
                    <measurement group_id="O2" value="18.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <p_value_desc>t(28)=0.11, p=0.91</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Collagen Content in Vaginal Muscularis, (Per-Protocol)</title>
        <description>Will assess hydroxy-proline assays as index of amount of collagen</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>Patients completing surgery with biopsy specimens available for analysis and who were adherent to study medication (&quot;per protocol&quot;)</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Collagen Content in Vaginal Muscularis, (Per-Protocol)</title>
          <description>Will assess hydroxy-proline assays as index of amount of collagen</description>
          <population>Patients completing surgery with biopsy specimens available for analysis and who were adherent to study medication (&quot;per protocol&quot;)</population>
          <units>mg collagen per mg muscularis wet weight</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.6" spread="146.1"/>
                    <measurement group_id="O2" value="94.86" spread="29.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <p_value_desc>t(18)=1.69, p=.10</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaginal Wall Degradative Activity, Muscularis, MMP-9</title>
        <description>Will assess zymograms for total matrix metalloprotease (MMP) 9 activity</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>All specimens with sufficient amount of tissue available for zymography analysis were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vaginal Wall Degradative Activity, Muscularis, MMP-9</title>
          <description>Will assess zymograms for total matrix metalloprotease (MMP) 9 activity</description>
          <population>All specimens with sufficient amount of tissue available for zymography analysis were used.</population>
          <units>Relative Units/mg protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.03" spread="15.06"/>
                    <measurement group_id="O2" value="132.34" spread="35.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>t(10)=2.76, p=0.020</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Estrone Levels, Surgery</title>
        <time_frame>Time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estrone Levels, Surgery</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="3.5"/>
                    <measurement group_id="O2" value="24.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <p_value_desc>t(23)=0.28, p=0.78</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Estradiol Levels, Baseline</title>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estradiol Levels, Baseline</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="3.7"/>
                    <measurement group_id="O2" value="8.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <p_value_desc>t(28)=0.67, p=0.51</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Estradiol Levels, Surgery</title>
        <time_frame>Time of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Estradiol Levels, Surgery</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="1.3"/>
                    <measurement group_id="O2" value="11.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>t(23)=1.23, p=0.24</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaginal Wall Composition: Lamina Propria (Intention to Treat)</title>
        <description>Will assess vaginal wall histology - thickness of lamina propria.</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vaginal Wall Composition: Lamina Propria (Intention to Treat)</title>
          <description>Will assess vaginal wall histology - thickness of lamina propria.</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1042.3" spread="169.8"/>
                    <measurement group_id="O2" value="895.1" spread="153.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaginal Wall Composition: Lamina Propria (Per-Protocol)</title>
        <description>Will assess vaginal wall histology - thickness of lamina propria</description>
        <time_frame>Time of surgery, i.e. 6-8 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vaginal Wall Composition: Lamina Propria (Per-Protocol)</title>
          <description>Will assess vaginal wall histology - thickness of lamina propria</description>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1133.4" spread="166.2"/>
                    <measurement group_id="O2" value="895.1" spread="153.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>hCOL3, (Per-Protocol)</title>
        <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>hCOL3, (Per-Protocol)</title>
          <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".92" lower_limit=".6" upper_limit="1.44"/>
                    <measurement group_id="O2" value=".37" lower_limit=".18" upper_limit=".95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lysyl Oxidase (LOX) (Per-Protocol)</title>
        <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Lysyl Oxidase (LOX) (Per-Protocol)</title>
          <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".74" spread=".14"/>
                    <measurement group_id="O2" value=".51" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LOXL1 (Per-Protocol)</title>
        <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>LOXL1 (Per-Protocol)</title>
          <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".64" spread=".12"/>
                    <measurement group_id="O2" value=".69" spread=".14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tropoelastin (Per-Protocol)</title>
        <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Tropoelastin (Per-Protocol)</title>
          <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".78" spread=".24"/>
                    <measurement group_id="O2" value=".69" spread=".11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>TGFB1 (Per-Protocol)</title>
        <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>TGFB1 (Per-Protocol)</title>
          <description>Data represent ratio of total mRNA relative to postmenopausal external control.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".61" spread=".13"/>
                    <measurement group_id="O2" value=".81" spread=".11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vaginal Wall Degradative Activity, Mucosa, MMP-9</title>
        <description>Will assess zymograms for total matrix metalloprotease (MMP) 9 activity</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>All specimens with sufficient amount of tissue available for zymography analysis were used.</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Vaginal Wall Degradative Activity, Mucosa, MMP-9</title>
          <description>Will assess zymograms for total matrix metalloprotease (MMP) 9 activity</description>
          <population>All specimens with sufficient amount of tissue available for zymography analysis were used.</population>
          <units>Relative Units/mg protein</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.97" spread="1.77"/>
                    <measurement group_id="O2" value="56.73" spread="23.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Blood Loss</title>
        <description>Intraoperative estimated blood loss</description>
        <time_frame>Time of surgery, i.e. after 6-8 weeks of intervention</time_frame>
        <population>In both study arms, 13 participants did undergo surgery and, therefore, had an estimated blood loss value available for analysis. However, one patient each from both study arms did not have biopsies taken (technical considerations/ intraoperative decision or conversion from total to supracervical hysterectomy without ability to collect biopsy).</population>
        <group_list>
          <group group_id="O1">
            <title>Premarin</title>
            <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Blood Loss</title>
          <description>Intraoperative estimated blood loss</description>
          <population>In both study arms, 13 participants did undergo surgery and, therefore, had an estimated blood loss value available for analysis. However, one patient each from both study arms did not have biopsies taken (technical considerations/ intraoperative decision or conversion from total to supracervical hysterectomy without ability to collect biopsy).</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285" spread="134"/>
                    <measurement group_id="O2" value="285" spread="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 - 8 weeks of preoperative use of vaginal estrogen (vs placebo) cream</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Premarin</title>
          <description>Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Premarin</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Annoyance with cream use</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>4 patients nonadherent to study protocol in the Premarin arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David D. Rahn, M.D.</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-648-6430</phone>
      <email>david.rahn@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

